Key Takeaways
Nurix Therapeutics gained nearly 29% in a month after Roche committed $700 million upfront to co-develop its BTK degrader, validating the company's protein degradation platform.
Nurix Therapeutics Inc. shares rallied 28.6% over the past month, far outpacing the industry's 2.5% gain, after the company signed an exclusive licensing and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg (NX-5948) across hematology, immunology and neurology indications.
"The partnership combines Nurix's expertise in targeted protein degradation with Roche's leading portfolio of B-cell targeted therapies and global commercial infrastructure," the companies said in a joint statement earlier this month.
Under the deal, Nurix receives $700 million upfront and is eligible for up to $2.3 billion in development, regulatory and commercial milestone payments. Nurix will fund 40% of development costs while Roche covers the remaining 60%. In the U.S., the companies will split profits and losses equally; outside the U.S., Roche will lead commercialization and pay Nurix tiered royalties ranging from the low to high teens.
The collaboration validates Nurix's drug discovery platform at a critical juncture. Bexobrutideg is an investigational, orally bioavailable, brain-penetrant Bruton's tyrosine kinase degrader — a novel mechanism that eliminates BTK protein rather than simply inhibiting it, potentially overcoming resistance that limits current BTK inhibitors like AbbVie Inc.'s Imbruvica and AstraZeneca Plc's Calquence. Early clinical results suggest the therapy could deliver superior efficacy and tolerability compared with existing options.
Bexobrutideg is expected to enter Phase III testing in second-line chronic lymphocytic leukemia later in 2026. Beyond oncology, the clinical development plan includes Phase II studies in multiple sclerosis and chronic spontaneous urticaria, broadening the drug's addressable market.
Nurix is also advancing partnered programs with Sanofi, which is moving the STAT6 degrader NX-3911 into clinical testing, and Gilead Sciences Inc., which is evaluating the IRAK4 degrader GS-6791 in a Phase I study. If those programs show encouraging results, Nurix can choose to co-develop them and share U.S. profits. The company also expects milestone payments from its collaborations with Gilead, Sanofi and Pfizer.
The Roche deal provides Nurix with a substantial cash runway, a critical factor for a clinical-stage biotech that has yet to generate product revenue. With $700 million upfront and a partner shouldering 60% of development costs, the company is well-positioned to fund its pipeline through multiple clinical readouts. Nurix shares, which carry a Zacks Rank #3 (Hold), have more than doubled the broader biotech sector's return over the past month as investors price in the reduced financial risk and expanded commercial potential of the bexobrutideg program.
This article is for informational purposes only and does not constitute investment advice.
